statins

ApprovedSmall molecule

Sanofi

statins is one of 382 small molecule programs targeting Cognitive impairment. It is currently in Approved.

Indications

Total Trials

Active Trials

381

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Acute Coronary SyndromeActive, not recruiting

HemorrhageActive, not recruiting

Familial HypercholesterolemiaActive, not recruiting

MyopathyActive, not recruiting

Myocardial InfarctionActive, not recruiting

AnemiaActive, not recruiting

Peripheral Arterial DiseaseActive, not recruiting

Breast CancerActive, not recruiting

COVID-19Active, not recruiting

Cognitive ImpairmentPhase 2/Phase 3

Active, not recruiting

Acute Coronary SyndromePreclinical

Active, not recruiting

HemorrhagePhase 3

Active, not recruiting

Familial HypercholesterolemiaPhase 2

Active, not recruiting

MyopathyApproved

Active, not recruiting

Myocardial InfarctionPreclinical

Active, not recruiting

AnemiaPhase 2/Phase 3

Active, not recruiting

Peripheral Arterial DiseasePreclinical

Active, not recruiting

Breast CancerPhase 3

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

statins

Sanofi

Approved

1 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

Adenocard

Astellas

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 7

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 8

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 9

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 10

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Statins

NCT03770702

Q4 2028

Phase 3Recruiting

Hemorrhage

NCT03936361

Clinical

Trials by Indication[1]

Statins2 trials

Statins and ARBs on Rheumatoid Activity

Recruiting·SSherief Abd-Elsalam·Phase 3·NCT03770702·45 enrolled

Differential Metabolic Effects of Statins

Completed·GGachon University Gil Medical Center··NCT00546559

Familial Hypercholesterolemia1 trial

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Completed· Sanofi logo

Sanofi·Phase 2·NCT02890992·42 enrolled

Hypercholesterolemia1 trial

Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)

Completed·OOrganon and Co·Phase 4·NCT00652847·1,140 enrolled

Type 2 Diabetes1 trial

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Completed· Sanofi logo

Sanofi·Phase 4·NCT02642159·413 enrolled

Peripheral Arterial Disease1 trial

Safety and Efficacy Study of Bosentan for Intermittent Claudication in Peripheral Arterial Disease

Completed·HHospital Universitario Getafe·N/A·NCT01738542·30 enrolled

15 more indications

Myopathy1 trial

Quality of Life in Patients With Statin-Associated Myopathy

Terminated·RRockefeller University·Phase 4·NCT00850460·14 enrolled

COVID-191 trial

Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study

Unknown status·KKarolinska Institutet··NCT04426084·22,784 enrolled

Anemia1 trial

Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia

Completed·—·Phase 2/3·NCT04301336·350 enrolled

Renal Transplant Recipients1 trial

Lipid Management in Renal Transplant Recipients Using Evolocumab.

Unknown status·—·Phase 4·NCT04608474·120 enrolled

Myocardial Infarction1 trial

Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction

Completed·UUniversity of Edinburgh·N/A·NCT05419583·60 enrolled

Chronic Coronary Syndrome1 trial

Chronic Coronary Syndrome Real Practice and Guidelines

Active, not recruiting·—··NCT06684366·300 enrolled

Cognitive impairment1 trial

Dapagliflozin Effect in Cognitive Impairment in Stroke Trial

Unknown status·JJaime Daniel Mondragon·Phase 2/3·NCT05565976·270 enrolled

Acute Coronary Syndrome1 trial

Prior Statin Use and Risk of CHF, ALO and Malignant Arrhythmia in Indonesian Post-Acute Coronary Syndrome Patients

Completed·TTarumanagara University··NCT03596931·130 enrolled

Elevated Cholesterol1 trial

Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins

Completed· Novartis logo

Novartis·Phase 1·NCT01859455·25 enrolled

Safety and Efficacy1 trial

A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH

Completed·AAkeso·Phase 2·NCT03933293·10 enrolled

Hemorrhage1 trial

Statins In Intracerbral Hemorrhage

Recruiting·—·Phase 3·NCT03936361·1,456 enrolled

Cardiovascular1 trial

Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment

Terminated·NNational Institute of Cardiology, Warsaw, Poland·N/A·NCT00968383·11 enrolled

Breast Cancer1 trial

Survival Benefits of Statins in Breast Cancer Patients

Unknown status·PPeking Union Medical College Hospital·Phase 3·NCT03971019·314 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

Terminated·PPronova BioPharma·Phase 2·NCT01972178·113 enrolled

Ischemic stroke1 trial

Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke

Unknown status·XXuanwu Hospital, Beijing··NCT06134635·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for statins. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — statins compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for statins. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

statins

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

Statins2 trials

Familial Hypercholesterolemia1 trial

Hypercholesterolemia1 trial

Type 2 Diabetes1 trial

Peripheral Arterial Disease1 trial

Myopathy1 trial

COVID-191 trial

Anemia1 trial

Renal Transplant Recipients1 trial

Myocardial Infarction1 trial

Chronic Coronary Syndrome1 trial

Cognitive impairment1 trial

Acute Coronary Syndrome1 trial

Elevated Cholesterol1 trial

Safety and Efficacy1 trial

Hemorrhage1 trial

Cardiovascular1 trial

Breast Cancer1 trial

Efficacy and Safety1 trial

Ischemic stroke1 trial

References

Drug Info

Quick Facts

Related News